468 related articles for article (PubMed ID: 11937555)
21. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
Lim SY; Laxmanan S; Stuart G; Ghosh SK
Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
[TBL] [Abstract][Full Text] [Related]
22. [Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma].
Wang FX; Zhang Y; Zhao B; Pan L; Zhang XJ; Luo JM; Dong ZR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1453-8. PubMed ID: 20030925
[TBL] [Abstract][Full Text] [Related]
23. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.
Cesco-Gaspere M; Zentilin L; Giacca M; Burrone OR
Scand J Immunol; 2008 Jul; 68(1):58-66. PubMed ID: 18482206
[TBL] [Abstract][Full Text] [Related]
24. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
25. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.
Timmerman JM; Caspar CB; Lambert SL; Syrengelas AD; Levy R
Blood; 2001 Mar; 97(5):1370-7. PubMed ID: 11222382
[TBL] [Abstract][Full Text] [Related]
26. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
Ciavarra RP; Vitetta ES; Forman J
J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
[TBL] [Abstract][Full Text] [Related]
27. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the V beta 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10.
Braciak TA; Pedersen B; Chin J; Hsiao C; Ward ES; Maricic I; Jahng A; Graham FL; Gauldie J; Sercarz EE; Kumar V
J Immunol; 2003 Jan; 170(2):765-74. PubMed ID: 12517939
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
29. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
30. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
31. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic manipulation of the GAT idiotypic cascade. Immunization of C57BL/6 mice by BALB/c anti-idiotypes stimulates similar strain-specific V genes as the original antigen.
Corbet S; Hirn M; Roth C; Theze J; Fougereau M; Schiff C
J Immunol; 1988 Aug; 141(3):779-84. PubMed ID: 3135311
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage.
Jensen S; Steffensen MA; Jensen BA; Schlüter D; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(8):4152-64. PubMed ID: 24043891
[TBL] [Abstract][Full Text] [Related]
34. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
35. Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.
Weaver EA; Chen CY; May SM; Barry ME; Barry MA
Hum Gene Ther; 2011 Sep; 22(9):1095-100. PubMed ID: 21770794
[TBL] [Abstract][Full Text] [Related]
36. Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma.
Wen YJ; Lim SH
Scand J Immunol; 1999 Sep; 50(3):296-301. PubMed ID: 10447939
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
38. Structural elements of a protein antigen determine immunogenicity of the embedded MHC class I-restricted T cell epitope.
Paster W; Kalat M; Zehetner M; Schweighoffer T
J Immunol; 2002 Sep; 169(6):2937-46. PubMed ID: 12218107
[TBL] [Abstract][Full Text] [Related]
39. DNA immunization induces protective immunity against B-cell lymphoma.
Syrengelas AD; Chen TT; Levy R
Nat Med; 1996 Sep; 2(9):1038-41. PubMed ID: 8782465
[TBL] [Abstract][Full Text] [Related]
40. H-2-linked Ir gene control of VH determinant(s)-specific helper T cells.
Kawahara DJ; Marrack P; Kappler JW
J Mol Cell Immunol; 1986; 2(5):255-64. PubMed ID: 2978232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
